"If you want to go fast, go alone. If you want to go far, go together."  //  www.theGoCARTcoallition.com

Mission: Be leading force in the field of cellular therapies and trusted partner to promote patient access to novel cellular therapies and to contribute health and well-being through multi-stakeholder collaboration on clinical data, standards of care, education and policy.

Vision: Create a platform driven by input of a diverse group of stakeholders who jointly develop projects that advance the field of cellular therapies in Europe.

Values:
- Patients-centred
- Build relationships and deliver results
- Creating value by sharing data
- Transparency breeds trust
- Grow and adapt

Work Package: Standards of Care

Success story!

Work group on site qualification: as a result of the collaboration in this work group Bristol Myers Squibb, Janssen, Kite and Novartis allow apheresis and cell therapy treatment centres to leverage their Joint Accreditation Committee (JACIE) accreditation. JACIE accredited centres will have the option of undergoing a reduced or remote audit focused on product-specific requirements for cell therapies.

This result clearly shows the power of multistakeholder collaboration to deliver continuous improvements and harmonisation, ultimately to support delivery of the highest quality of care to patients.

Pharmacist work group: the aim is to make the Institutional Readiness Guidelines for CAR T-cell therapies and 4 categories of ATMPs that were developed by the UK Pharmacy Working Group for ATMPs applicable to other European countries.

Apheresis work group: the aim is to make the Recommendations on Apheresis for ATMP manufacture that were developed by Sample UK applicable to other European countries.

Work Package: Data Harmonisation

The work package is working towards finalisation of the updated EBMT Cellular Therapies data collection form after a multi-stakeholder revision of the document. The main challenge is to balance the requirements of regulatory authorities and pharmaceutical companies and the feasibility to collect this real-world data by the centres.

Work Package: Education

GoCART Clinical Case Discussion series for Physicians: every 3rd Tuesday of the month from 4-5 pm CET two real-life clinical cases are presented and discussed with three experts in the field.

GoCART Nurses Best Practice Sharing series: these webinars take place every 3rd Thursday of the month from 4.30-5.00 pm CET. The meetings are focussed on different aspects of CAR T-cell therapies, starting with theoretical background followed by a case study to highlight the ‘in practice’ learning.

Register on our website to join these free events!

Work Package: Scientific Excellence

In the first call for collaborative research proposals the following proposals were selected to receive a research grant:

B. Glass & P. Corradini: Comparison of allogeneic hematopoietic stem cell transplantation with chimeric antigen receptor T-cells in relapsed and refractory large B cell lymphoma (LWP & German Lymphoma Alliance)

S. Giebel & V. Ortiz: Impact of preceding therapy on the efficacy, safety and feasibility of anti-CD19 CAR T-cells in acute lymphoblastic leukemia (ALWP, CTIWP)

M. Doglio: Autoimmune and auto-inflammatory complications after CAR-T cell therapy (ADWP, CTIWP, TCWP)

Join us? Questions or suggestions?

Would you like to join the GoCART Coalition? Participate in our activities? Have new proposals or ideas? Please contact:

Yolanda Cabrerizo (Y.Cabrerizo@ehaweb.org) or Sofie Terwel (Sofie.Terwel@ebmt.org).